Clinical Trial Detail

NCT ID NCT03513562
Title Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ohio State University Comprehensive Cancer Center
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib + Venetoclax

Age Groups: adult senior

No variant requirements are available.